Rosuvastatin pharmacokinetics in Asian and White subjects wild-type for both OATP1B1 and BCRP under control and inhibited conditions

The FDA recommends rosuvastatin dosage reductions in Asian patients because pharmacokinetic studies have demonstrated an approximate two-fold increase in median exposure to rosuvastatin in Asian subjects when compared to Caucasian controls. Yet, no explanation for this ethnic difference has been con...

Full description

Saved in:
Bibliographic Details
Published in:J Pharm Sci
Main Authors: Wu, Hsin-Fang, Hristeva, Nadya, Chang, Jae, Liang, Xiaorong, Li, Ruina, Frassetto, Lynda, Benet, Leslie Z.
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675025/
https://ncbi.nlm.nih.gov/pubmed/28385543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2017.03.027
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items